Business ❯Pharmaceutical Industry

Market Performance

Stock Market Stock Prices Sales Growth Stock Analysis

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations

Rollout is planned for the 2025-26 respiratory virus season under a new policy limiting COVID-19 boosters to high-risk groups.

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

Novo Nordisk Shares Plunge After Weight-Loss Drug Trial Falls Short